Precipio has commercially launched HemeScreen, a test for mutations in hematologic cancers. The test measures for mutations in the CALR, JAK2, and MPL genes, as well as in exon 12 of JAK2, all of which are critically important to developing a clinical roadmap for the patient, Precipio said. The company will offer the assay through its CLIA laboratory in New Haven, Connecticut, and will also offer a set of RUO reagents to other reference labs to perform the test in their CLIA laboratories.
Seq2Know Celiac Disease Testing
Seq2Know is offering testing for celiac disease. The firm's test includes sequencing of the DQA1 and DQB1 genes that have been associated with celiac disease. All tests will be ordered directly from Seq2Know.com and will be reviewed by PWNHealth to ensure the appropriateness of the test, the company said.
Stratify Genomics Prompt Prostate Cancer Test
Stratify Genomics has launched Prompt, its new lab-developed test to track a man's genetic predisposition to prostate cancer. According to the firm, Prompt incorporates genetic information from several prostate cancer-risk associated SNPs. Using population-based analyses, the test reports how many men out of 100 with a given genetic score would go on to develop prostate cancer. Clinicians can perform the test with a cheek swab sample to help men know their individual risk and potentially identify high-risk individuals.
For more new products and services, please visit the New Products page on our website.